Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.65 EUR -2.99%
Market Cap: 14.7m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

Celyad Oncology SA
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Celyad Oncology SA
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Celyad Oncology SA
XBRU:CYAD
Depreciation & Amortization
€626k
CAGR 3-Years
-29%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
M
MDxHealth SA
NASDAQ:MDXH
Depreciation & Amortization
$7.1m
CAGR 3-Years
31%
CAGR 5-Years
18%
CAGR 10-Years
37%
Galapagos NV
AEX:GLPG
Depreciation & Amortization
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxurion NV
XBRU:OXUR
Depreciation & Amortization
€268k
CAGR 3-Years
-40%
CAGR 5-Years
-41%
CAGR 10-Years
N/A
No Stocks Found

Celyad Oncology SA
Glance View

Market Cap
14.7m EUR
Industry
Biotechnology

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 88 full-time employees. The company went IPO on 2013-07-05. The firm is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The firm develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The firm's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). The company also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

CYAD Intrinsic Value
0.03 EUR
Overvaluation 96%
Intrinsic Value
Price

See Also

What is Celyad Oncology SA's Depreciation & Amortization?
Depreciation & Amortization
626k EUR

Based on the financial report for Jun 30, 2024, Celyad Oncology SA's Depreciation & Amortization amounts to 626k EUR.

What is Celyad Oncology SA's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-14%

Over the last year, the Depreciation & Amortization growth was -28%. The average annual Depreciation & Amortization growth rates for Celyad Oncology SA have been -29% over the past three years , -14% over the past five years .

Back to Top